摘要
目的探讨乳腺癌新辅助化疗前后MCM7蛋白的表达状况,分析其与化疗效果的关系。方法采用免疫组织化学法检测55例乳腺癌新辅助化疗前后标本中MCM7的表达。结果新辅助化疗有效率为76.36%。化疗前MCM7蛋白阳性表达显著高于化疗后(P<0.01)。化疗有效组(42例增殖期)MCM7蛋白阳性表达显著高于无效组(13例静止期)(P<0.01)。结论ET方案新辅助化疗有较好的疗效,可能通过抑制MCM7蛋白的表达来阻止乳腺癌细胞的增殖。MCM7蛋白高表达者化疗更为敏感,MCM7可作为临床指导乳腺癌化疗并预测化疗敏感性的分子生物学指标。
Objective To study the expressions of MCM7 before and after neoadjuvant chemotherapy in patients with breast cancer, and to analyze its xelationship with response to neoadjuvant chemotherapy. Methods An immunohistochemistry was used to measure the expressions of MCM7 before and after neoadjuvant chemotherapy for 55 cases of breast cancer. Results The overall response rate to neoadjuvant chemotherapy was 76.36%. The positive expression of MCM7 before neoadjuvant chemotherapy was significantly higher than that after neoadjuvant chemotherapy （ P 〈 0.01）. The positive expression of MCM7 in the group of response to neoadjuvant chemotherapy （42 cases in proliferative phase） was significantly higher than that of no response to neoadjuvant chemotherapy （13 cases in quiescence phase） （ P 〈 0.01）. Conclusion Neoadjuvant chemotherapy with ET regimen is effective, and it may inhibit the proliferation of breast cancer cell by down- regulation of the expression of MCM7. Patients with high expression of MCM7 were more likely to respond to chemotherapy. The expression of MCM7 as biological marker could be a guide for chemotherapy and prediction for its response to chemotherapy in breast cancer.
出处
《右江民族医学院学报》
2009年第4期572-573,共2页
Journal of Youjiang Medical University for Nationalities
